Skip Navigation



Annals of Oncology Advance Access published online on November 2, 2009
Annals of Oncology, doi:10.1093/annonc/mdp494
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Martin-Castillo, B.
Right arrow Articles by Menendez, J. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin-Castillo, B.
Right arrow Articles by Menendez, J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letter to the editor

Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical–translational research experience at the Catalan Institute of Oncology

The first 10% of the full text of this article appears below.

At the time of writing, a search in ClinicalTrials.gov yields six open studies evaluating the efficacy and safety of treating cancer patients with the antidiabetic biguanide metformin. At the European Institute of Oncology in Italy, the Division of Cancer Prevention and Genetics is planning a presurgical randomized, double-blind, placebo-controlled phase II biomarker trial in which breast cancer (BC) patients not suitable for neo-adjuvant therapy will be randomly assigned to either metformin . . . [Full Text of this Article]

funding

disclosure

B. Martin-Castillo1,2, J. Dorca1,2, A. Vazquez-Martin1,2, C. Oliveras-Ferraros1,2, E. Lopez-Bonet2,3, M. Garcia1,4, S. del Barco1,2 and J. A. Menendez1,2,*

1 Translational Research Unit, Catalan Institute of Oncology
2 Molecular Oncology, Girona Biomedical Research Institute, Girona
3 Department of Pathology, Dr. Josep Trueta University Hospital of Girona, Girona
4 Department of Clinical Oncology, IDIBELL, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona Catalonia, Spain

* (E-mail: jmenendez@iconcologia.net)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?